KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Short term Debt (2018 - 2025)

Aquestive Therapeutics has reported Short term Debt over the past 8 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Short term Debt at $10.0 million for Q4 2025, up 38338.46% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (up 38338.46% YoY), and the annual figure for FY2025 was $10.0 million, up 38338.46%.
  • Short term Debt for Q4 2025 was $10.0 million at Aquestive Therapeutics, up from $6.3 million in the prior quarter.
  • Over the last five years, Short term Debt for AQST hit a ceiling of $18.7 million in Q4 2022 and a floor of $22000.0 in Q4 2023.
  • Median Short term Debt over the past 5 years was $4.9 million (2021), compared with a mean of $6.4 million.
  • Biggest five-year swings in Short term Debt: crashed 99.88% in 2023 and later soared 38338.46% in 2025.
  • Aquestive Therapeutics' Short term Debt stood at $2.0 million in 2021, then surged by 823.46% to $18.7 million in 2022, then crashed by 99.88% to $22000.0 in 2023, then rose by 18.18% to $26000.0 in 2024, then soared by 38338.46% to $10.0 million in 2025.
  • The last three reported values for Short term Debt were $10.0 million (Q4 2025), $6.3 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.